CD4 and neoplasm: Notwithstanding the high luminescence (probably due to the most peripheral portion of the live tumor), we found larger necrosis, a lower ratio of CD4+/CD8+ TILs, and a high ratio of CD8+/CD25+ in the TNBC tumors that were concomitantly treated with MB/oncolytic viruses and pembrolizumab than control tumors, which is in agreement with previously published human studies of TNBC [38,40,41].